- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00433979
Study of Pharmacokinetics in HIV-infected Women
Predictors of Antiretroviral Pharmacokinetics in HIV-infected Women With Virologic Suppression on Combination Antiretroviral Therapy
Women represent an increasing proportion of HIV cases globally and in Canada, yet are underrepresented in clinic trials. It is therefore critical to conduct this study on antiretroviral (ARV) pharmacokinetics (PK) in women to obtain additional information on ARV drug levels in women and their relation to adverse events (AEs).
The hypothesis for this study is three-fold:
- that the mean drug levels (Cmin and Cmax) of ARVs will be significantly higher in our female population as compared to the mean drug levels in the historical HIV population (which is primarily men)
- that ARV drug levels, particularly Cmin, are associated with body weight in women
- that higher ARV drug levels, particularly Cmax, are associated with higher frequency and severity of AEs.
The objectives of this study are as follows:
Primary objectives:
- To demonstrate that levels of Protease Inhibitors (PIs) and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) are significantly higher in our female population as compared to the mean drug levels in the historical general population (which is primarily men).
- To determine the association between PI and NNRTI minimum concentration (Cmin) and body weight in our female population.
Secondary objectives
- To determine the association between maximum concentration (Cmax) and the frequency and severity of AEs as measured by the proportion of patients with grade 2 or higher laboratory or clinical AEs and the Symptom Index Score in women.
- To determine the association between ARV drug levels and age, race, height, body mass index, adherence, hormonal levels and therapy, menstruation history, duration of HIV infection, duration on ARV therapy, baseline viral load, baseline CD4 count, present CD4 count, hepatitis B or C infection, class of ARVs, presence of ritonavir and other medications.
Study Overview
Detailed Description
Predictors of antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy
Background
Women in Canada constitute the fastest growing population groups at risk for infection with HIV and AIDS. Women now represent approximately 40% of all AIDS cases worldwide and approximately 20% of cases in Canada. Although the AIDS epidemic has been ongoing for more than 20 years, surprisingly little is known about the differential efficacy and toxicity of various antiretroviral (ARV) drugs in women as compared to men. This gap in knowledge is a result of the initial exclusion of and continued underrepresentation of women in ARV clinical trials. Many studies suggest that HIV-infected women taking ARV treatment (ART) have more adverse events (AEs) than men, especially in relationship to systemic symptoms like diarrhea, as well as organ toxicity, including hepatotoxicity, lactic acidosis, peripheral neuropathy and, notably, lipodystrophy. Currently, the occurrence and management of AEs is the most important issue in the treatment of HIV. Understanding the reasons for the differences of AEs in HIV-infected women is critical and has yet to be evaluated within a large cohort. It is unknown whether these differences relate to hormonal influences, drug metabolism, adherence, fat distribution, body size or other factors. Some small studies have found that drug levels (e.g. Cmin, Cmax, AUC) are higher in women and are associated with increased toxicity. Ultimately, we plan to conduct a randomized clinical trial (RCT) to assess the utility of therapeutic drug monitoring (TDM) and ARV drug dose adjustment on the frequency of AEs in women. Prior to conducting this RCT, it is critical to conduct this study on ARV pharmacokinetics (PK) in women to obtain additional information on ARV drug levels in women and their relation to AEs.
Hypothesis
The hypothesis for this study is three-fold:
- that the mean drug levels (Cmin and Cmax) of ARVs will be significantly higher in our female population as compared to the mean drug levels in the historical HIV population (which is primarily men)
- that ARV drug levels, particularly Cmin, are associated with body weight in women
- that higher ARV drug levels, particularly Cmax, are associated with higher frequency and severity of AEs.
Patient population
Eighty HIV-infected women from 8 Canadian sites who have been on their first combination ART regimen containing either a PI or an NNRTI (since these are the ARV agents eligible for PK analysis) for at least three months and who have evidence of full virologic suppression (HIV RNA VL less than 50 copies/mL) on at least two occasions at least one month apart.
Objectives Primary objectives
- To demonstrate that the Cmin and Cmax of PIs and NNRTIs are significantly higher in our female population as compared to the mean drug levels in the historical general population (which is primarily men).
- To determine the association between PI and NNRTI Cmin and body weight in our female population.
Secondary objectives
- To determine the association between Cmax and the frequency and severity of AEs as measured by the proportion of patients with grade 2 or higher laboratory or clinical AEs and the Symptom index score in women.
- To determine the association between ARV drug levels and age, race, height, body mass index, adherence, hormonal levels and therapy, menstruation history, duration of HIV infection, duration on ARV therapy, baseline VL, baseline CD4 count, present CD4 count, hepatitis B or C infection, class of ARVs, presence of ritonavir and other medications.
Study design
The study will be a cross-sectional study with ARV drug levels (Cmin and Cmax) measured weekly for three weeks Three samples will be taken from each subject to reduce variability due to both technologic and biologic sources. Data will be collected on demographic characteristics, clinical disease and ARV history and on clinical toxicities at the first visit. Blood work will be carried out on the first visit to assess for laboratory toxicity and hormonal levels.
Data analysis
Drug levels will be summarized with the mean of the 3 values for Cmin and Cmax for each woman for their PI or NNRTI and compared to the mean values of the general HIV population. Cmin and Cmax will be classified into high and low levels with a high level defined as less than or equal to 1.5 X arithmetic population mean for each drug. Characteristics of patients with high drug levels will be compared to those of patients with low drug levels. Univariate and multivariate logistic regression models will be used to identify independent associations of patient characteristics with high drug levels. The proportions of patients with AEs and the median number of AEs per patient will be compared between patients with high Cmax and patients with low Cmax.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada, G1V 4G2
- Chuq/Chul
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 1Y6
- St. Paul's Hospital
-
Vancouver, British Columbia, Canada, V6H 3N1
- Children and Women's Hospital
-
Vancouver, British Columbia, Canada, V6Z 2C7
- Downtown Infectious Diseases Clinic
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- Capital District Health Authority
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- Hamilton Health Sciences - McMaster University
-
Ottawa, Ontario, Canada, K1N 6N5
- University of Ottawa Health Services
-
Ottawa, Ontario, Canada, K1Y 4E9
- Ottawa Health Research Institute
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael's Hospital
-
Toronto, Ontario, Canada, M5B 1L6
- Canadian Immunodeficiency Research Collaborative
-
Toronto, Ontario, Canada, M5G 2N2
- University Health Network - Toronto General Hospital
-
Windsor, Ontario, Canada, N8W 1E3
- Windsor Regional Hospital HIV Care Program
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1T7
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CHUM)
-
Montreal, Quebec, Canada, H2X 2P4
- Montreal Chest Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient must be HIV infected
- Patient must be 18 years old or older
- Patient must be a biologic woman
- Patient must be taking her first combination ARV regimen that includes a PI or an NNRTI for the past three months with no changes in any agent of the combination in that period (first combination ARV regimen is defined as a regimen started when the patient was ARV-naïve; however switches are allowed as long as the switches are not for virologic failure)
- Patient must be taking either a PI or an NNRTI but not both
- If taking a PI, patient must be taking only one PI excluding low dose ritonavir used as boosting
- Patient must have a viral load < 50 copies/mL on two occasions at least 1 month apart including a value within three months before the baseline visit
- Patient has to have signed and dated a full informed consent
Exclusion Criteria:
- Patient who would have difficulty participating in a trial due to non-adherence or substance abuse
- Patient who is pregnant or breast-feeding
- Patient with a malignancy receiving systemic chemotherapy
- Patient with end stage organ disease
- Patient with other significant non-HIV underlying disease that might impinge upon disease progression or death
- Patient who is not taking standard dosing of a PI or NNRTI as listed in Appendix G
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Prospective
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mona R Loutfy, MD FRCPC MPH, Women's College Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Anti-Infective Agents
- Antiviral Agents
- Anti-Retroviral Agents
Other Study ID Numbers
- HHP-79215
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on antiretroviral treatment
-
French National Agency for Research on AIDS and...National Institutes of Health (NIH)CompletedHIV Infection | TuberculosisCambodia
-
Juan A. ArnaizCompleted
-
Objectif Recherche Vaccins SIDAFondation Bettencourt-SchuellerCompleted
-
Rockefeller UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Montefiore Medical... and other collaboratorsCompleted
-
National Institute of Allergy and Infectious Diseases...WithdrawnHIV InfectionsUnited States, Puerto Rico
-
University of Cape TownLondon School of Hygiene and Tropical Medicine; Medical Research Council, South... and other collaboratorsUnknownTuberculosisSouth Africa
-
National Institute of Allergy and Infectious Diseases...Withdrawn
-
Ukrainian Institute on Public Health PolicyCompleted
-
University of Alabama at BirminghamJohns Hopkins University; Birmingham AIDS Outreach; AIDS UnitedCompletedHIV Infection | HIV Care Loss to Followup
-
Massachusetts General HospitalNational Institute of Allergy and Infectious Diseases (NIAID)Completed